TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with LDL-C \>100 mg/dL \& on a stable dose of atorvastatin 20 mg~Exclusion Criteria:~* Pregnant or lactating women or intending to become pregnant~* Patient with sensitivity or intolerance to ezetimibe or atorvastatin~* Patient with diabetes or coronary heart disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Atorvastatin 40mg tablet + Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day).
- 2 (Type: EXPERIMENTAL): Atorvastatin 40mg Pbo tablet + Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Renal transplant recipients greater than 18 years of age, who have given written consent~Exclusion Criteria:~* Taking medications that may alter the metabolism of tacrolimus or mycophenolate sodium~* Experienced an acute rejection episode prior to the pharmacokinetic profile collection~* Serum creatinine \>2 mg/dL~* Neutropenia (Absolute Neutrophil Count \< 1.3x10\^3/mL)~* Received a previous transplant other than a kidney~* Receiving chronic steroids at time of transplant~* Known hypersensitivity to tacrolimus, mycophenolate mofetil, mycophenolate sodium, mycophenolic acid or any of its excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Myfortic - Fed State (Type: EXPERIMENTAL): Mycophenolate sodium taken with a meal.
- Myfortic - Fasting State (Type: EXPERIMENTAL): Mycophenolate sodium taken separately from food by 2 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who participated in and completed either study CGAL or study CGAM.~* Investigator judges the participant as reliable to follow all study procedures, keep all study visits, and be compliant with study requirements.~Exclusion Criteria:~* Current enrollment in or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device (with the exception of Study CGAL or Study CGAM).~* Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP) antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF) (with the exception of Study CGAL or Study CGAM).~* A history of migraine variants that could implicate or could be confused with ischemia.~* Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins.~* A history or presence of other medical illness that indicates a medical problem that would preclude study participation.~* Evidence of significant active or unstable psychiatric disease, in the opinion of the investigator.~* Women who are pregnant or nursing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Galcanezumab (Type: EXPERIMENTAL): Participants received 300 milligram (mg) Galcanezumab administered subcutaneously (SC) up to once a month.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed, newly diagnosed, advanced primary non-small cell lung cancer (NSCLC) (adenocarcinoma, large cell carcinoma, squamous cell carcinoma, or unspecified), designated as 1 of the following stages:~  * Selected stage IIIB (excluding Pancoast tumors)~    * T4 lesion due to malignant pleural effusion OR~   * Multiple lesions in a single lobe containing a T3 or T4 primary~ * Stage IV (any T, any N, M1)~ * Recurrent disease after prior surgery and/or radiotherapy~* Measurable or evaluable disease outside of prior radiation port~* No bronchoalveolar carcinoma~* No brain metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Zubrod 0-1 (for age 70 and over) (Age 70 and older with Zubrod 0-1 stratum closed to accrual as of 2/15/2003)~* Zubrod 2 (for age 18 and over)~Life expectancy:~* Not specified~Hematopoietic:~* Absolute granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than upper limit of normal (ULN)~* SGOT/SGPT no greater than 2 times ULN if alkaline phosphatase is no greater than ULN OR~* Alkaline phosphatase no greater than 4 times ULN if SGOT/SGPT are no greater than ULN~Renal:~* Not specified~Other:~* No prior severe hypersensitivity to docetaxel or other drugs formulated with polysorbate 80~* No grade 2 or greater sensory neuropathy~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other adequately treated stage I or II cancer in complete remission~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior or concurrent biologic therapy for NSCLC~* No concurrent filgrastim (G-CSF)~Chemotherapy:~* No prior systemic chemotherapy for NSCLC~Endocrine therapy:~* No prior or concurrent hormonal therapy for NSCLC~Radiotherapy:~* See Disease Characteristics~* At least 3 weeks since prior radiotherapy and recovered~* Concurrent palliative radiotherapy to small-field nonmeasurable lesions (i.e., painful bony lesions) allowed~* No other concurrent radiotherapy~Surgery:~* See Disease Characteristics~* At least 3 weeks since prior thoracic or other major surgery and recovered

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Golimumab in Participants With Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have had psoriatic arthritis (PsA) for at least 6 months prior to the first administration of study agent~* Have a diagnosis of active PSA as defined by 5 or more swollen joints and 5 or more tender joints at Screening and at Baseline and C-reactive protein \>=0.6 milligram per deciliter (mg/dL) at Screening~* Have active plaque psoriasis or a documented history of plaque psoriasis~* Have active PsA despite current or previous disease-modifying antirheumatic drugs (DMARD) and/or nonsteroidal anti-inflammatory drug (NSAID) therapy. DMARD therapy is defined as taking a DMARD for at least 3 months, or evidence of DMARD intolerance. NSAID therapy is defined as taking an NSAID for at least 4 weeks or evidence of NSAID intolerance~Exclusion Criteria:~* Have other inflammatory diseases that might confound the evaluations of benefit of Golimumab therapy, including but not limited to rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, or Lyme disease~* Are pregnant, nursing, or planning a pregnancy or fathering a child while enrolled in the study or within 4 months after receiving the last administration of study agent~* Have used any biologic agents that are targeted for reducing tumor necrosis factors (TNF) alpha, including but not limited to Infliximab, Etanercept, Adalimumab, Golimumab, and Certolizumab Pegol~* Have ever used cytotoxic drugs, including Chlorambucil, Cyclophosphamide, Nitrogen mustard, or other Alkylating agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group 1: Placebo (Type: PLACEBO_COMPARATOR): Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20. At Week 24, all participants receiving placebo will begin receiving intravenous infusions of golimumab 2 milligram per kilogram (mg/kg) at Week 24, 28 and thereafter every 8 weeks up to Week 52.
- Treatment Group 2: Golimumab (Type: EXPERIMENTAL): Participants will receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52. At Week 24, participants will receive a placebo infusion to maintain the blind.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Pharmacokinetics of a Single Large Dose of Vitamin D3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* healthy with limited sun exposure of less than 10 hours per week and daily milk consumption of less than 0.47 L (16 oz.).~Exclusion Criteria:~* those with granulomatous conditions, liver disease, kidney disease, or diabetes and those taking anticonvulsants, barbiturates, or steroids in any form.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- cholecalciferol (Type: EXPERIMENTAL): A single dose of 100,000 IU vitamin D
- Control (Type: NO_INTERVENTION): No drug was given

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a BMI ≥28 kilogram/square meter (kg/m²), or ≥24 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease~* Have a history of at least one self-reported unsuccessful dietary effort to lose body weight~Exclusion Criteria:~* Have Diabetes Mellitus~* Have a self-reported change in body weight \>5 kg within 3 months prior to screening~* Have obesity induced by other endocrinological disorders~* Have had a history of chronic or acute pancreatitis~* Have a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder within the last 2 years~* Have any lifetime history of a suicide attempt~* Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 10 Milligrams (mg) Tirzepatide (Type: EXPERIMENTAL): Participants received maintenance dose 10 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, and then 10 mg tirzepatide administered subcutaneously (SC) once weekly (QW).
- 15 mg Tirzepatide (Type: EXPERIMENTAL): Participants received maintenance dose 15 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and then 15 mg tirzepatide administered SC QW.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo SC QW.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed acute symptomatic proximal DVT without symptomatic PE~Exclusion Criteria:~* Legal lower age limitations (country specific)~* Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT and/or PE~* Other indication for VKA than DVT and/or PE~* The pre-randomization anti-coagulant treatment (Criteria # 4) has been prolonged from 36 hours to a maximum of 48 hours.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Xarelto, BAY59-7939) (Type: EXPERIMENTAL): Participants were to receive rivaroxaban 15 mg oral tablet twice daily for 3 weeks, followed by 20 mg once daily
- Enoxaparin/VKA (Type: ACTIVE_COMPARATOR): Participants were to receive 1.0 mg/kg enoxaparin twice daily (subcutaneous) for at least 5 days, plus vitamin K antagonist (VKA) (oral) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 to 3.0)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* BMI \>=30 kg/m2 and \<50 kg/m2 or a BMI \>=27 kg/m2 and \<50 kg/m2 in the presence of controlled hypertension and/or treated or untreated dyslipidemia~* Must have a stable weight, i.e., increasing or decreasing not more than 5% in the 3 months before screening~* Serum creatinine \<=1.5 mg/dL for men and \<=1.4 mg/dL for women at screening~* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels within 2 times the upper limit of normal (ULN) and bilirubin within the normal range, unless the findings are consistent with Gilbert's disease~* fasting plasma glucose PG \<7.0 mmol/L (126 mg/dL) at screening~Exclusion Criteria:~* A history of hereditary glucose-galactose malabsorption or primary renal glycosuria~* An established diagnosis of diabetes mellitus or treatment with glucose lowering drugs at screening~* A history of reactive hypoglycemia or of symptomatology possibly due to hypoglycemia~* Fasting triglyceride level \>6.78 mmol/L (600 mg/dL) at screening~* History of obesity with a known cause (e.g., Cushing's disease)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Canagliflozin 50 mg (Type: EXPERIMENTAL): Each patient will receive 50 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
- Canagliflozin 100 mg (Type: EXPERIMENTAL): Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
- Canagliflozin 300 mg (Type: EXPERIMENTAL): Each patient will receive 300 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Each patient will receive matching placebo once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Assess Safety, PK and PD Parameters of CDR132L

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stable heart failure of ischemic origin~Exclusion Criteria:~* Heart failure of non-ischemic origin (hypertensive heart disease, myocarditis, alcoholic cardiomyopathy and cardiac dysfunction due to rapid atrial fibrillation),

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CDR132L (Type: EXPERIMENTAL): None
- Saline (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Type 1 Diabetes mellitus (T1DM)~* Central laboratory C-peptide \< 0.7 ng/ml (0.23 nmol/L)~* Insulin use for at least 12 months per patient reported or medical records~* Method of insulin administration (MDI or CSII) must have been unchanged for at least 3 months prior to screening~* Subjects must be on a total insulin dose of ≥ 0.3 U/kg/day for at least 3 months prior to screening~* If on MDI insulin administration, subject must be on ≥ 3x injections per day~* Screening Visit: Central laboratory HbA1c ≥ 7.7% and ≤ 11.0%~* Body mass index (BMI) ≥ 18.5 kg/m2~Exclusion Criteria:~* History of Type 2 Diabetes mellitus (T2DM) or maturity onset diabetes of the young (MODY), pancreatic surgery, or chronic pancreatitis that could result in decreased beta cell capacity~* Taking metformin and/or thiazolidinediones within 2 months prior to screening~* Taking any antidiabetic medication (other than insulin), within 1 month prior to screening~  - Taking GLP-1 receptor agonist within 2 months prior to screening for once weekly administration and within 1 month prior to screening for once or twice daily administration~* History of diabetes ketoacidosis requiring medical intervention within 1 month prior to screening~* History of hospital admission for glycemic control (either hyperglycemia or hypoglycemia) within 1 month prior to screening~* Frequent episodes of severe hypoglycemia (more than one episode requiring medical assistance, emergency care), and/or glucagon therapy administered by a third-party individual within 1 month prior to screening~* History of Addison's disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm A: Dapagliflozin (Type: EXPERIMENTAL): Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
- Arm B: Dapagliflozin (Type: EXPERIMENTAL): Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
- Arm C: Placebo for Dapagliflozin (Type: PLACEBO_COMPARATOR): Placebo tablet orally, once daily for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have premalignant lesions.~* Lesion sites include oral cavity, oropharynx, and larynx.~* Must have at least a \>20 pack-year history of smoking.~* Must have a Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status of 0-1.~* Participants must be 18 years of age or older.~* No contraindications for laryngoscopy and biopsy.~* Adequate liver function.~* Must have hemoglobin and hematocrit levels at or above the lower limit of the normal range.~* Participants must have prothrombin time (PT)/partial thromboplastin time (PTT) levels at or above the lower limit of the normal range.~* Women of child-bearing potential must have a negative serum pregnancy test within 72 hours of receiving treatment.~* Must be able to swallow the oral dose of erlotinib and celecoxib.~* Participants must be disease free.~* Final eligibility will be determined by the health professionals conducting the trial.~Exclusion Criteria:~* Participants with acute intercurrent illness or those who had surgery within the preceding 4 weeks unless they have fully recovered.~* History of previous malignancies unless the cancer was stage I or II and rendered free of disease more than 1 year.~* Pregnant or breast feeding.~* Not practicing adequate contraception if the participants are of child bearing potential.~* Female patients who have a positive pregnancy test.~* History or recent myocardial infarction.~* Hypertension not adequately controlled by medication.~* Documented history of coagulopathy.~* Documented history of congestive heart failure (CHF) greater than New York Heart Association (NYHA) Grade II.~* Participants who were taking COX-2 inhibitors or EGFR tyrosine kinase inhibitors within 3 months of study entry.~* Documented history or interstitial lung disease.~* Known connective tissue disease.~* History of nonsteroidal antiinflammatory drug (NSAID)-induced ulcers or those who are at risk for a GI ulcer.~* Participated in a clinical trial of an investigational drug within 12 months prior to enrollment.~* Final eligibility will be determined by the health professionals conducting the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Erlotinib & Celecoxib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete